Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

TSXV:BTI - Post Discussion

Bioasis Technologies Inc. > New Zacks Report - $0.60 USD/Share Price Target
View:
Post by AlfredSisley on Feb 09, 2021 4:09pm

New Zacks Report - $0.60 USD/Share Price Target

On page 1: "We expect clinical trials to begin in 2021 for both candidates." (001 &007) 

https://s1.q4cdn.com/460208960/files/News/2021/Zacks_SCR_Research_02092021_BIOAF_Vandermosten.pdf
Comment by zwerp2000 on Feb 09, 2021 4:36pm
Looks like John expects the company to announce data on several different programs this quarter. Hopefully that will be the case. I'd think that he has talked to the company before writing this 
Comment by Finallytherock on Feb 09, 2021 4:37pm
From what I know of John, he does speak to the companies he writes on so maybe he has been advised by the ceo data is still coming this quarter. I agree, let's hope this is the case
Comment by narmac on Feb 09, 2021 4:55pm
,,hummm,,,, .60 cents USD,,,,aaaccchhhhh,,,,,,way tooooo loooowww,,,,,,,,,,,,,not sure that most of these groups assessing such plays as we have with BTI get direct access,,,but actually,,from what I have read,,,,,they generally do get invites to sit down with managment,,its a synergy,,,especially those analysts who are considered the prestigous ones ,,some get paid,,some dont,,,,not sure how many ...more  
Comment by barsax on Feb 09, 2021 5:00pm
the price target (itself) is largely irrelevant...as long as its 50-75% higher than where its currently trading.  As we move up (to daaaa moooooon) he will adjust his target price.  We're all playing games, analysts play games too - standard inducstry practice - which I'm sure an old codger like you knows very well
Comment by prophetoffacts on Feb 09, 2021 5:42pm
This post has been removed in accordance with Community Policy
Comment by chrispi on Feb 10, 2021 7:25am
analysts can be extremely conservative in their price targets and can be totally off in under-appreciating the share price appreciation that can happen when a biotech releases great data results. Take Ocugen (OCGN) for example, just in the past two weeks they recently released some results and partnership news. On Feb 1/2021 OCGN closed at $1.81 On Feb 4/2021, with the stock trading at $2.81 H.C ...more  
Comment by prophetoffacts on Feb 09, 2021 4:45pm
This post has been removed in accordance with Community Policy
Comment by Finallytherock on Feb 09, 2021 4:48pm
Hope so. As I said, I am sure John spoke to the company before writing this article
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities